KalVista Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- KalVista Pharmaceuticals's estimated annual revenue is currently $16.4M per year.
- KalVista Pharmaceuticals's estimated revenue per employee is $150,734
- KalVista Pharmaceuticals's total funding is $239.7M.
Employee Data
- KalVista Pharmaceuticals has 109 Employees.
- KalVista Pharmaceuticals grew their employee count by 5% last year.
KalVista Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP, Clinical | Reveal Email/Phone |
2 | VP Finance | Reveal Email/Phone |
3 | SVP, Development | Reveal Email/Phone |
4 | VP CMC | Reveal Email/Phone |
5 | VP Research | Reveal Email/Phone |
6 | Senior Director Regulatory Affairs | Reveal Email/Phone |
7 | Director, Data Management and Systems | Reveal Email/Phone |
8 | Chief Medical Officer | Reveal Email/Phone |
9 | Associate Director | Reveal Email/Phone |
10 | Director DMPK and Screening | Reveal Email/Phone |
KalVista Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is KalVista Pharmaceuticals?
KalVista is a clinical stage pharmaceuticals company focused on the discovery, development, and commercialization of small molecule protease inhibitors.
keywords:N/A
$239.7M
Total Funding
109
Number of Employees
$16.4M
Revenue (est)
5%
Employee Growth %
N/A
Valuation
N/A
Accelerator
KalVista Pharmaceuticals News
KalVista Pharmaceuticals (NASDAQ:KALV) Upgraded at Zacks Investment Research. Posted by admin on Apr 21st, 2022. Share on Twitter Share on Facebook Share on...
KalVista Pharmaceuticals (NASDAQ:KALV) versus Aridis Pharmaceuticals (NASDAQ:ARDS) Head-To-Head Analysis. Posted by admin on Apr 16th, 2022.
KalVista Pharmaceuticals (NASDAQ:KALV) Downgraded by Zacks Investment Research to Sell. Posted by admin on Apr 14th, 2022.
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--Mar 19, 2021-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced today that Nancy Stuart has ...
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--Mar 11, 2021-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an operational update ...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $38.5M | 109 | 8% | N/A |
#2 | $15.8M | 109 | -6% | $18.5M |
#3 | $10.5M | 110 | 10% | $366.3M |
#4 | $16M | 110 | -4% | N/A |
#5 | $19.8M | 110 | -3% | N/A |